OnCusp Therapeutics
We Bring Oncology Innovation to Life
28 employees · est. 2021 · New York, United States
Prelude Therapeutics
Precision Oncology, Redefined.
126 employees · est. 2016 · Wilmington, United States
Prelude Therapeutics is the older company (2021 vs 2016); Prelude Therapeutics is the larger of the two.
Side-by-Side Comparison
| Metric | OnCusp Therapeutics | Prelude Therapeutics |
|---|---|---|
| Founded | ||
| Founded | 2021 | 2016 older |
| Headquarters | ||
| Headquarters | New York, United States | Wilmington, United States |
| Employees | ||
| Employees | 28 | 126 larger |
| Industry | ||
| Industry | Biotechnology, Health Care, Pharmaceutical | Biopharma, Biotechnology, Health and Wellness |
| Funding Stage | ||
| Funding Stage | Series A | Post Ipo Equity |
| Total Funding | ||
| Total Funding | $125.00M | $147.00M |
| Funding Rounds | ||
| Funding Rounds | 2 | 4 |
| Services | ||
| Services | Development of Oncology Treatments, Clinical R&D, Partnership and Collaboration, Business Development | Development of precision oncology medicines, Innovative cancer drug discovery, Targeted protein degradation technology, Pipeline of clinical and preclinical programs |
| Target Customers | ||
| Target Customers | Cancer Patients, Healthcare Providers, Pharmaceutical Companies, Research Institutions | Cancer Patients, Oncologists, Healthcare Providers, Pharmaceutical Partners |
| Taxonomy | ||
| Taxonomy | Biopharmaceutical, Oncology, Cancer Treatments, Preclinical Innovation, Clinical Validation, Drug Development, Biotech Startups, Global Partnerships, Oncology Assets, Innovation Acceleration, Research Asset Transformation, Oncology Medication Innovation | Precision Oncology, Clinical-stage, Cancer Therapeutics, Small Molecule Compounds, Targeted Cancer Pathways, SMARCA2 Degrader, CDK9 Inhibitor, CDK4/6 Inhibitor, Cancer Resistance Mechanisms, Oncology Drug Development, Orally Bioavailable Therapies, Novel Cancer Therapies, Healthcare Innovation, Cancer Research |
| Website | ||
| Website | oncusptx.com | preludetx.com |
About OnCusp Therapeutics
OnCusp Therapeutics is a promising player in the biopharmaceutical industry, founded in 2021 with headquarters in the United States. Their mission, elegantly encapsulated in their slogan, "We Bring Oncology Innovation to Life," reflects a dedication to evolving preclinical discoveries into validated...
About Prelude Therapeutics
Prelude Therapeutics, founded in 2016, is a United States-based clinical-stage precision oncology company redefining cancer treatment with a focus on developing innovative drug candidates that target critical cancer cell pathways. The company uniquely positions itself within the Biopharma, Biotechno...
We will tell you when either one moves
BounceWatch watches OnCusp Therapeutics and Prelude Therapeutics for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at OnCusp Therapeutics and Prelude Therapeutics — by email.
Frequently Asked Questions
Compare OnCusp Therapeutics with someone else
Start typing a company name or domain.
Compiled from the BounceWatch company index. We last looked at OnCusp Therapeutics on 9 Jun 2026, and Prelude Therapeutics on 27 Nov 2025. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
